Medicare's New GLP-1 Bridge Program
- Jun 3
- 2 min read
What Beneficiaries Need to Know Before July 1
Wegovy. Zepbound. Ozempic. Mounjaro.
For years, these highly discussed GLP-1 medications have largely remained out of reach for many Medicare beneficiaries unless they were prescribed for conditions like Type 2 diabetes, obstructive sleep apnea (OSA), or cardiovascular disease — and even then, costs could still be substantial.
Beginning July 1st, that changes.
Under Medicare's new GLP-1 Bridge Program, certain qualifying GLP-1 medications will be available to Medicare Beneficiaries at a $50 copay.
Specifically for weight loss and weight management.
Which Medications Are Included?
Starting July 1, CMS has announced that the following medications qualify under the GLP-1 Bridge program when prescribed specifically for weight loss and weight management:
Wegovy®
Zepbound® (Kwikpen only)
Foundayo®
NOTE: If one of these medications is being prescribed for anything other than weight loss/weight management (Type-2 Diabetes, Obstructive Sleep Apnea), then it will continue to be covered through your Medicare Part D coverage.
Do I Need to Enroll or Opt in?
Most beneficiaries will not need to complete a separate enrollment process.
To access medications through the GLP-1 Bridge program:
The beneficiary must be enrolled in Medicare Part D coverage (either a standalone Part D plan or a Medicare Advantage plan with drug coverage).
A healthcare provider must determine the patient meets eligibility requirements.
The provider must submit a prior authorization request.
Once approved, the prescription can be filled through the program.
Unlike many Medicare benefits that vary by plan, the GLP-1 Bridge Program applies across all Medicare plans with prescription drug coverage (Part D & Medicare Advantage).
Good News: If your Medicare Plan has a deductible, it does not apply to this program.
How Long Will the Program Last?
When originally announced, the GLP-1 Bridge program was expected to run only through the end of 2026.
The Center for Medicare & Medicaid Services (CMS) has since extended the program through December 31, 2027.
By then, CMS hopes to have established a more long-term solution for obesity medication coverage. At this point, Medicare beneficiaries should view the GLP-1 Bridge as a temporary but important expansion of access — not necessarily a permanent Medicare benefit.
Why Wegovy, Zepbound, & Foundayo?
From CMS:
These are the three medications that manufacturers agreed to make available through the program and that are FDA-approved specifically for chronic weight management.
Why not Ozempic or Mounjaro?
Although Ozempic and Mounjaro contain active ingredients that are closely related to Wegovy and Zepbound, they are FDA-approved for Type 2 diabetes rather than weight loss.
The Bottom Line on Medicare's GLP-1 Program
The Medicare GLP-1 Bridge Program represents a significant change for beneficiaries seeking access to weight-loss medications. While the program is available nationwide and applies to all Medicare plans with prescription drug coverage, eligibility requirements, prior authorizations, and medication-specific guidelines can still create confusion.
If you have questions about how this program works, whether your current coverage may be affected, or how Medicare changes could impact your healthcare costs, the team at Seniority Benefit Group is here to help.
Comments